XU HƯỚNG MỚI TRONG ĐIỀU TRỊ BỆNH VIÊM KHỚP DẠNG THẤP
Main Article Content
Abstract
Rheumatoid arthritis (RA) is a specific and chronic systemic autoimmune disease that includes different degrees of joint, extra-articular, and systemic manifestations. The most severe consequences of RA are the destruction of joint structures and lead to disability. The early use of Disease-modifying antirheumatic drugs (DMARDs) at the time of definitive diagnosis is the cornerstone of rheumatoid arthritis treatment strategies. Thanks to advances in molecular biology and genetics, the pathogenesis of rheumatoid arthritis has been clearly defined in the past two decades, and the treatment of RA has made remarkable strides. Several generations of DMARDs have been developed, which are classical DMARDs (Methotrexate), biologics (Tocilizumab), and in the future, the targeted therapy DMARDs (anti-JAK). In addition, the treatment trend of rheumatoid arthritis has changed dramatically. Early detection, early aggressive treatment, “Treatment to target” and early use of classical DMARDs in combination with new biologic drugs to achieve remission as quickly as possible are optimal measures that help change outcomes for patients with rheumatoid arthritis.
Keywords
Rheumatoid arthritis, Disease-modifying antirheumatic drugs, Treatment to target
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Aletaha D., Neogi T., Silman A. J., et al. (2010), 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 69 (9), pp. 1580-8.
3. Arya V, Malaviya AN, Raja RR (2007), CDAI (clinical disease activity index) in rheumatoid arthritis: Cut-off values for classification into different grades of disease activity, Indian Journal of Rheumatology, 2(3), pp. 91–94.
4. Benjamin O., Bansal P., Goyal A., et al. (2021), Disease Modifying Anti-Rheumatic Drugs (DMARD), StatPearls, Treasure Island (FL).
5. Farrugia M., Baron B. (2016), The role of TNF-alpha in rheumatoid arthritis: A focus on regulatory T cells, J Clin Transl Res, 2 (3), pp. 84-90.
6. Fraenkel L., Bathon J. M., England B. R., et al. (2021), 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Arthritis Care Res (Hoboken), 73 (7), pp. 924-939.
7. Gary S. Firestein, Ralph C. Budd, Sherine E. Gabriel, et al. (2021), Clinical Features of Rheumatoid Arthritis, Firestein & Kelley's Textbook of Rheumatology, Elsevier, Philadelphia, pp. 1236-1256.
8. J. Larry Jameson (2017), Rheumatoid Arthritis, Harrison’s Principles of Internal Medicine, McGraw-Hill Global Education, New York, pp. 2527-2540.
9. Kerrigan S. A., McInnes I. B. (2020), Reflections on 'older' drugs: Learning new lessons in rheumatology, Nat Rev Rheumatol, 16 (3), pp. 179-183.
10. Kucharz E. J., Stajszczyk M., Kotulska-Kucharz A., et al. (2018), Tofacitinib in the treatment of patients with rheumatoid arthritis: Position statement of experts of the Polish Society for Rheumatology, Reumatologia, 56 (4), pp. 203-211.
11. Lau C. S., Chia F., Dans L., et al. (2019), 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis, Int J Rheum Dis, 22 (3), pp. 357-375.
12. Rohini Handa (2021), Rheumatoid Arthritis, Clinical Rheumatology, Springer, Singapore, pp. 51-66.
13. Smolen J. S., Landewe R. B. M., Bijlsma J. W. J., et al. (2020), EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, Ann Rheum Dis, 79 (6), pp. 685-699.
14. Smolen J. S., Breedveld F. C., Schiff M. H., et al. (2003), "A simplified disease activity index for rheumatoid arthritis for use in clinical practice", Rheumatology (Oxford), 42 (2), pp. 244-57.
15. Van Riel P. L. (2014), "The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28)", Clin Exp Rheumatol, 32 (5 Suppl 85), pp. S-65-74.
16. Weinblatt M. E. (2013), "Methotrexate in rheumatoid arthritis: A quarter century of development", Trans Am Clin Climatol Assoc, 124, pp. 16-25.
17. Gary S. Firestein, Ralph C. Budd, Sherine E. Gabriel, et al. (2021), "Treatment of Rheumatoid Arthritis", Firestein & Kelley's Textbook of Rheumatology, Elsevier, Philadelphia, pp. 1258-1282.